PTPI Stock Performance, Insider Transaction and News

PTPI - Petros Pharmaceuticals, Inc.

Market Cap	8.26M	P/E	-	EPS this Y	66.50%	Ern Qtrly Grth	-
Income	-20.64M	Forward P/E	-	EPS next Y	48.80%	50D Avg Chg	40.00%
Sales	4.12M	PEG	-	EPS past 5Y	-	200D Avg Chg	29.00%
Dividend	N/A	Price/Book	0.53	EPS next 5Y	-	52W High Chg	-59.00%
Recommedations	2.00	Quick Ratio	0.93	Shares Outstanding	9.61M	52W Low Chg	326.00%
Insider Own	8.44%	ROA	-30.61%	Shares Float	8.94M	Beta	2.30
Inst Own	2.16%	ROE	-63.77%	Shares Shorted/Prior	235.11K/260.70K	Price	3.91
Gross Margin	70.21%	Profit Margin	-171.24%	Avg. Volume	413,508	Target Price	1.00
Oper. Margin	-160.46%	Earnings Date	-	Volume	69,348	Change	-1.01%

Healthcare | Drug Manufacturers - Specialty & Generic | United States

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals, Inc. News

11/16/24	Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
09/11/24	Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
09/03/24	Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/17/24	Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
07/29/24	Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
07/16/24	Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
05/29/24	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
08:15 AM	Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
05/14/24	Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
05/14/24	Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
04/23/24	Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
04/16/24	Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
04/02/24	Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
03/19/24	Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
02/14/24	Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
01/24/24	Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
01/17/24	Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
12/12/23	Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
12/12/23	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider

PTPI Chatroom

Rico999 Posted - 59 minutes from now

$PTPI One PR to reveal AI partner name, cancel millions offering, IND submission, this will be parabolic bounce above $1.

PenkeTrading Posted - 2 hours ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Petros Pharmaceuticals Inc. Is that bullish or bearish? $PTPI #Petros #RsiOversold #NASDAQ

NewMike Posted - 4 hours ago

$PTPI come on, stay down since Noone wants so I can load up more

lsuoak19 Posted - 4 hours ago

$PTPI bullish hammer candle on the daily chart

RAGC Posted - 5 hours ago

$PTPI what a big pos. This entire market is full of p*ssies

NachoBusiness Posted - 5 hours ago

$PTPI who got suckered into buying at .30?

Finnisher2M Posted - 5 hours ago

$PTPI 🙏

MontrealYul Posted - 5 hours ago

$PTPI Why this pump AH ?

NachoBusiness Posted - 5 hours ago

$PTPI shorted right back down

Gurkripa81 Posted - 5 hours ago

$PTPI Heavily shorted..OTC FDA news any day..easy $1

NewMike Posted - 5 hours ago

$PRFX $PTPI I'm telling you guys I alert early! Be early don't chase

mikeyd Posted - 5 hours ago

$PTPI AH chicanery and tomfoolery if you will, c’mon you fanuch , that’s all you got? We want .60+ or go back in your hole

Gurkripa81 Posted - 5 hours ago

$PTPI It's moving AH $WORX $BDRX

Photokd97 Posted - 5 hours ago

$PTPI Now all we need is some VOLUME!

SCinvestor7 Posted - 6 hours ago

$PTPI ?

Gurkripa81 Posted - 6 hours ago

$PTPI .25 dark pool wall gone LFG

WolfofFraudStreet Posted - 8 hours ago

$PTPI I have no idea why people do not know how to post the facts back up with the links . But the 180 extension is true. Here is the link. And as long as the Naked short stop the short sht show then, this give the stock plenty of time to move up. presshttps://www.sec.gov/Archives/edgar/data/1815903/000141057824001943/tmb-20240930x10q.htm

WolfofFraudStreet Posted - 9 hours ago

$PTPI This is still a naked short game. The naked short shorted at an average of 76% the last two days. So, if you bought these days, you are adding to problem becuase you bought naked shares and not public floated shares. The naked shorts will never stop shorting until everyone stops buying. In order for the naked short mechanism to work it requires new buyers and the reason it work is becuase reailer alway buy in the low prices becuase of the percieved low price value I tested a buy yesterday into the ask price wall and it did not move instead the naked short added more naked short shares at the low bid price. 87% shorting proves that the nakeds are. If the naked short were not here then the wall would have moved up, but it did not the short just keep on adding new shares. Right now we do not know if they are going to allow the squeeze or take it down to a reverse split price. That is why I will not buy anymore shares until I see the the low bid price move up 20-50%

Gurkripa81 Posted - 10 hours ago

$PTPI 35% float owned by two institution https://www.sec.gov/Archives/edgar/data/1646799/000121390024097237/ea022071815-13ga5intra_petro.htm

Gurkripa81 Posted - 10 hours ago

$PTPI https://www.sec.gov/Archives/edgar/data/1698148/000149315224046058/formsc13ga.htm

Gurkripa81 Posted - 10 hours ago

$PTPI

Gurkripa81 Posted - 10 hours ago

$PTPI

NewMike Posted - 11 hours ago

$CDT $CNSP called both YESTERDAY when they were nice and low and quiet. Be early, don't chase!! Both big winners premarket, CNSP still waiting for major spike imo. Take a look at $APDN and $PTPI as they could be due!!! Glta! 💰 🤑 💸 💲 🪙 💶 💰

Conquer_ Posted - 11 hours ago

$PTPI